Pope Francis (Credit: X)
Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.
A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.
Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.
Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.
Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.
Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.
Credit: PA Media
For the first time, a baby boy has been born to a mother with a womb transplanted from a deceased donor at Queen Charlotte’s and Chelsea hospital in London.
Weighing merely 3.09kg (6lb 13oz), Hugo Powell was born to Grace Bell and Steve Powell from Kent, right before Christmas 2025. "It's simply a miracle. I never, ever thought that this would be possible," Bell said. "I'm the happiest I've ever been in my life. When I was 16, I was told that this would never be possible," she said of her son's birth.
The father added: "When he came over the curtain, it was just sort of overwhelming emotions. I felt like I wanted to cry, but couldn't. From where we started - first meeting - to where we are today, with Hugo, is nothing short of a miracle after everything we've been through. It just felt quite unreal at the time, because this has been a long journey for us both."
The couple also paid tribute to the "kindness and selflessness" of their transplant donor and her family for their "incredible gift", while also thanking medical teams in Oxford and London who supported their journey.
"There are no words to say thank you enough to my donor and her family. Their kindness and selflessness to a complete stranger is the reason I have been able to fulfil my lifelong dream of being a mum.
"I hope they know that my child will always know of their incredible gift, and the miracle that brought him into this world," Bell said.
Bell, an IT programme manager, was born with Mayer-Rokitansky-Kuster-Hauser (MRKH), a disorder that causes the vagina and uterus to be underdeveloped or absent. MRKH syndrome is also called:
While women with MRKH syndrome have normal external genitalia, functioning ovaries, breast and pubic hair development, they are unable to carry a pregnancy and rely on either surrogacy or a womb transplant, as in the case of Bell.
There are two versions of the disorder:
However, these genetic changes have been found in only a small number of affected people and subsequent studies have not identified a clear association between MRKH syndrome and any specific environmental factors. It remains unclears whether they actually cause MRKH syndrome.
Treatment for MRKH depends on the patient's goals and symptoms and some options include:
"I still can't believe that I'm here today and I've gone through this. It's just amazing."
At the age of 16, the new mother was told she wouldn't be able to carry her own child. However, in 2024 she received a phone call saying a womb had been donated and a transplant was possible, a moment she recalls left her "in complete shock" and "really excited".
Bell's womb transplant operation lasted 10 hours and took place at The Churchill Hospital in Oxford in June 2024 After her transplant surgery, she began fertility treatments several months after the transplant in 2024 and her son was born a year later.
According to The Guardian, Bell's transplanted womb will be removed when the couple have finished having children, to save her from a lifetime of taking immunosuppressant drugs.
Credits: iStock
15 US states sued President Donald Trump led administration after the Department of Health and Human Services led by Health Secretary Robert F Kennedy Jr. revised vaccine schedule that led to coverage fall from 17 to 11 diseases for children. These 15 states are led Democrats and on Tuesday, they announced suing the Trump administration over unscientific grounds of releasing a new vaccine schedule.
The lawsuit has been filed by a coalition of 14 attorneys general and the governor of Pennsylvania. They have asked the courts to nullify the administration's decision to reduce the number of diseases children are routinely immunized from 17 to 11.
The lawsuit also challenges "the unlawful replacement" of members of the federal Advisory Committee on Immunization Practices, who recommend vaccines for Americans. The lawsuit names the Department of Health and Human Services and Health Secretary Robert F Kennedy Jr as defendants. It also names the Centers for Disease Control and Prevention and its acting director, Dr Jay Bhattacharya.
Read: CDC Vaccine Schedule: Coverage Falls From 17 to 11 Diseases For Children
In a news briefing on Tuesday, Rob Bonta, attorney general of California said, "H.H.S. Secretary R.F.K. Jr. and his C.D.C. are flouting decades of scientific research, ignoring credible medical experts, and threatening to strain state resources and make America’s children sicker.” Bonta continued, "The fact is, vaccines save lives and save our state’s money."
The lawsuit also notes that the administration's revised vaccination schedule was unscientific and relied instead on comparisons to countries that are different than the United States.
Kris Mayes, attorney general of Arizona, as reported by The New York Times said that the latest vaccine schedule "copies" Denmark's recommendation, where the country already has a nationalized health care and the population is fraction of that of the US. "Copying Denmark’s vaccine schedule without copying Denmark’s health care system doesn’t give families more options — it just leaves kids unprotected from serious diseases."
Also Read: Wegovy And Ozempic Will Cost Less In 2027, Novo Nordisk Slashes Weight Loss Drugs Prices By Half

On January 5, 2026, the federal health officials led by RFK Jr. announced that the new Centers for Disease Control and Prevention (CDC), vaccine schedule will include routine shots for 11 diseases for children. This is down from 17 diseases, which were earlier included.
Under the revised schedule, vaccines for a limited number of diseases remain universally recommended for children. These include protection against measles, polio, and whooping cough, which are still considered essential routine immunizations.
The most controversial change is the narrowing of recommendations for several common childhood vaccines. Immunization against the following illnesses is now advised only for high-risk children or after consultation with a health care provider:
Covid-19 vaccination has also shifted to a consultation-based recommendation rather than routine use for all children.
This means shots that were once automatically given at set ages, including at birth, during infancy, and in adolescence, may now depend on individual medical discussions rather than standard guidance.
Credits: iStock
Wegovy and Ozempic will cost less by January 1 of 2027 as manufacturer Novo Nordisk announced that the prices will be cut in half. The manufacturer said that the popular GLP-1 weight loss drugs will be as much as 50 per cent.
The manufacturer noted that this cut applies to all doses and the semaglutide tablet Rybelsus will now cost $675 a month. Rybelsus has been approved by the US Food and Drug Administration (FDA) to reduce the risk of heart attacks in those with diabetes.
Read: Doctor Explains Why Weight Loss Drugs Like Ozempic Are Truly A Medical Breakthrough
In a statement to PEOPLE, Jamey Millar, Executive Vice President, US Operations of Novo Nordisk Inc. said, "There are more than 100 million people living with obesity and over 35 million with type 2 diabetes and, for some, list price has been a real barrier to access and affordability."
Wegovy injections and pills currently cost $1,349.02 a month, whereas Ozempic and Rybelus cost $1,027.51. These figures have been emailed to PEOPLE by Novo Nordisk.
Read: GLP-1 Drugs Don’t Just Curb Appetite; They Rewire the Brain, Shows Study
People with commercial insurance pay $25 a month, whereas those using cash pay between $149 to $499. Patients on Medicare will pay $274 per month.

GLP-1 drugs mimic the action of the natural hormone GLP-1 to regulate blood sugar and promote weight loss. They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.
Read: Zepbound Outperforms Other Weight Loss Drugs, More Details Inside
In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.
These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.
In September 2025, WHO added GLP-1 drugs to its list of essential medicines, but only for treating diabetes, not for obesity alone. The new guideline extends that conversation, offering a more formal stance on their use in obesity management. The recommendations were developed by a committee of experts in obesity, pharmacology, and public health, following requests from several WHO member states. They also align with approvals already granted by regulators like the US FDA.
© 2024 Bennett, Coleman & Company Limited